Goldman Sachs
CANF

Goldman Sachs’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

Goldman Sachs’s Portfolio CANF Stock Details CANF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-3
Closed -$23K – 7270
2015
Q1 		$23K Buy
+3
New +$36.1K ﹤0.01% 6881

Other funds holding CANF

TAM
Taylor Asset Management Toronto, Ontario, Canada $154M AUM 10.32% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
MC
Menta Capital San Francisco, California $236M AUM 6.6% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MFS
MSI Financial Services Springfield, Massachusetts $3.07B AUM 10.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Goldman Sachs's CANF Position: Q2 2015 in Review

Goldman Sachs sold out of Can-Fite BioPharma American Depositary Shares (CANF) in Q2 2015, closing a stake of 3 shares — an estimated $23K sold.

Goldman Sachs first reported a position in CANF in Q1 2015 and held it in 1 quarter. The position peaked at $23K in Q1 2015. 5 funds tracked by Wall St. Rank hold CANF as of Q2 2015.

  • Goldman Sachs reported no remaining Can-Fite BioPharma American Depositary Shares position as of Q2 2015 after selling out during the quarter.
  • Goldman Sachs sold 3 Can-Fite BioPharma American Depositary Shares shares in Q2 2015, an estimated $23K.
  • Goldman Sachs first reported a position in Can-Fite BioPharma American Depositary Shares in Q1 2015 and held it in 1 quarter.
  • Goldman Sachs's Can-Fite BioPharma American Depositary Shares position peaked at $23K in Q1 2015.
  • 5 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q2 2015.

Based on Goldman Sachs's 13F filing for Q2 2015, filed 14 Aug 2015.